Wednesday, 4 December 2019

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.


No comments:

Post a Comment